Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

Company Overview - Shattuck Labs, Inc. is a biotechnology company focused on developing novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for inflammatory and immune-related diseases [1][3] - The company is headquartered in Austin, Texas, and Durham, North Carolina [3] Product Development - Shattuck is developing SL-325, a potential first-in-class Death Receptor 3 (DR3) blocking antibody aimed at achieving a complete and durable blockade of the DR3/TL1A pathway [2][3] - Preclinical studies of SL-325 show high affinity binding and superior activity compared to TL1A antibodies, supporting the rationale for targeting the TNF receptor DR3 [2] - SL-325 has completed a GLP toxicology study in non-human primates, with an Investigational New Drug (IND) filing anticipated in the third quarter of 2025 [2] Upcoming Events - Company management will participate in a panel discussion and one-on-one meetings at the Leerink Partners Therapeutics Forum on July 8-9, 2025, in Boston, MA [1][2] - The session titled "TL1A: Pioneering a New MOA in IBD and Beyond" will be moderated by analysts from Leerink, with Shattuck's CEO, Taylor Schreiber, presenting [2]